Author:
Mignon Laurence,Stahl Stephen M.
Abstract
The World Health Organization estimates that depression is the fourth leading cause of disability worldwide with a lifetime prevalence of ∼15% to 20%. While the antidepressants currently on the market will be effective in most patients, a significant number of patients will experience residual symptoms, treatment-resistance, and relapse. The recent Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study has shed some light on the reality of antidepressant treatment. At first, only one-third of patients on citalopram monotherapy remitted. The other two-thirds who failed to remit saw their likelihood of remission decrease with each successive trial of another antidepressant monotherapy. Thus, after four successive monotherapies were tried over the course of one year, (ie, after four treatments each lasting 12 weeks), only two-thirds of patients achieved remission (Figure 1). Besides this poor prognosis, the patients who required more treatment cycles to get better also had a higher likelihood of relapsing. Once patients reach that point, they are considered treatment-resistant.
Publisher
Cambridge University Press (CUP)
Subject
Psychiatry and Mental health,Neurology (clinical)
Reference23 articles.
1. Combining antidepressant therapies form the initiation of treatment: a paradigm shift for major depression;Stahl;J Clin Psychiatry.
2. Women's Mental Health: Depression and Anxiety
3. Eszopiclone Co-Administered With Fluoxetine in Patients With Insomnia Coexisting With Major Depressive Disorder
4. Depression and Suicide in Children and Adolescents
5. Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report;Nierenberg;Psychol Med.,2009
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献